(2S,3R,4S,5S,6R)-2-[[(2R,3S,4R,5R,6R)-4,5-Dihydroxy-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Term ID

CHEBI:146523

Synonyms

alpha-D-gluco-hexopyranosyl-(1->4)-[alpha-D-gluco-hexopyranosyl-(1->6)]-alpha-D-gluco-hexopyranosyl-(1->4)-D-gluco-hexopyranose
Glc(a1-4)[Glc(a1-6)]Glc(a1-4)Glc
WURCS=2.0/2,4,3/[a2122h-1x_1-5][a2122h-1a_1-5]/1-2-2-2/a4-b1_b4-c1_b6-d1

Definition

References

GlyGen:G01580PZ
GlyTouCan:G01580PZ

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2S,3R,4S,5S,6R)-2-[[(2R,3S,4R,5R,6R)-4,5-Dihydroxy-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype where environments contain (2S,3R,4S,5S,6R)-2-[[(2R,3S,4R,5R,6R)-4,5-Dihydroxy-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype modified by environments containing (2S,3R,4S,5S,6R)-2-[[(2R,3S,4R,5R,6R)-4,5-Dihydroxy-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype affecting (2S,3R,4S,5S,6R)-2-[[(2R,3S,4R,5R,6R)-4,5-Dihydroxy-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Human Disease Model